In addition, the Company will webcast the question-and-answer breakout session immediately following its presentation at
The live webcast of the presentation and breakout session can be accessed under “Events and Presentations” on the Investors section of the Viridian website at viridiantherapeutics.com. A replay of the webcast will be available on the Company’s website after the event until
About
Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company recently initiated its first global Phase 3 trial called ‘THRIVE’ to evaluate the safety and efficacy of VRDN-001 in patients with active TED. Viridian is also evaluating VRDN-001 in a Phase 2 proof-of-concept trial in patients with chronic TED. In addition to its intravenously administered VRDN-001 program, the Company is advancing two candidates for its subcutaneous strategy with the goal of providing a more conveniently administered therapy to patients with TED. Viridian is developing multiple preclinical assets in autoimmune and rare diseases.
Viridian is based in
Investor and Media Contact:
Senior Vice President, Corporate Affairs and Investor Relations
IR@viridiantherapeutics.com
Source:
![](https://ml.globenewswire.com/media/Yjk0OTE1ZTctYTg5YS00YzVhLTk4OTMtZmJkMzc5ZjI5NWM2LTUwMDEwNDAzNQ==/tiny/Viridian-Therapeutics-Inc.png)
2023 GlobeNewswire, Inc., source